Cooper Investors PTY Ltd. Has $12.08 Million Stock Holdings in Stevanato Group S.p.A. $STVN

Cooper Investors PTY Ltd. grew its holdings in Stevanato Group S.p.A. (NYSE:STVN) by 4.4% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 668,494 shares of the company’s stock after purchasing an additional 28,265 shares during the quarter. Stevanato Group comprises 5.5% of Cooper Investors PTY Ltd.’s portfolio, making the stock its 4th biggest holding. Cooper Investors PTY Ltd. owned approximately 0.22% of Stevanato Group worth $12,080,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in STVN. Conestoga Capital Advisors LLC boosted its stake in Stevanato Group by 7.6% during the 1st quarter. Conestoga Capital Advisors LLC now owns 8,491,751 shares of the company’s stock valued at $116,762,000 after purchasing an additional 602,050 shares during the period. Kornitzer Capital Management Inc. KS acquired a new stake in Stevanato Group in the 1st quarter valued at approximately $1,856,000. Van Berkom & Associates Inc. increased its position in Stevanato Group by 2,944.2% in the 1st quarter. Van Berkom & Associates Inc. now owns 170,994 shares of the company’s stock worth $2,351,000 after buying an additional 165,377 shares during the period. Jennison Associates LLC increased its position in Stevanato Group by 13.7% in the 4th quarter. Jennison Associates LLC now owns 1,772,896 shares of the company’s stock worth $35,671,000 after buying an additional 213,602 shares during the period. Finally, Roubaix Capital LLC lifted its holdings in shares of Stevanato Group by 96.6% during the first quarter. Roubaix Capital LLC now owns 385,316 shares of the company’s stock worth $5,298,000 after buying an additional 189,343 shares during the last quarter.

Insider Transactions at Stevanato Group

In related news, Director Karen Flynn sold 1,493 shares of the company’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of €17.09, for a total value of €25,515.37. Following the completion of the transaction, the director directly owned 5,757 shares in the company, valued at approximately €98,387.13. This represents a 20.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director William J. Federici sold 1,493 shares of the firm’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of €17.09, for a total value of €25,515.37. Following the completion of the transaction, the director directly owned 26,991 shares of the company’s stock, valued at approximately €461,276.19. This trade represents a 5.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 5,972 shares of company stock valued at $102,061.

Analyst Ratings Changes

Several research firms have recently weighed in on STVN. Weiss Ratings raised Stevanato Group from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, July 16th. Wolfe Research began coverage on shares of Stevanato Group in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $21.00 target price on the stock. Finally, TD Cowen upgraded shares of Stevanato Group to a “strong-buy” rating in a research note on Wednesday, June 17th. Two investment analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Buy”.

Stevanato Group Stock Up 0.6%

STVN stock opened at €19.78 on Wednesday. Stevanato Group S.p.A. has a twelve month low of €12.89 and a twelve month high of €28.00. The company has a market cap of $5.99 billion, a PE ratio of 33.52, a price-to-earnings-growth ratio of 1.84 and a beta of 0.77. The business’s 50-day simple moving average is €18.70 and its 200 day simple moving average is €16.97. The company has a quick ratio of 1.11, a current ratio of 1.63 and a debt-to-equity ratio of 0.21.

Stevanato Group (NYSE:STVN) last posted its quarterly earnings results on Friday, May 8th. The company reported €0.11 EPS for the quarter, missing the consensus estimate of €0.12 by (€0.01). Stevanato Group had a net margin of 11.76% and a return on equity of 10.27%. The firm had revenue of €273.57 million during the quarter. During the same period last year, the business posted $0.10 earnings per share. The firm’s quarterly revenue was up 6.6% on a year-over-year basis. On average, research analysts anticipate that Stevanato Group S.p.A. will post 0.71 earnings per share for the current year.

Key Stories Impacting Stevanato Group

Here are the key news stories impacting Stevanato Group this week:

• Positive Sentiment: Stevanato reported second-quarter revenue of €302.0 million, an 8% year-over-year increase. High-value solutions accounted for 45% of revenue, and gross profit margin improved, indicating continued demand for the company’s drug-containment, drug-delivery and diagnostic products. Stevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026
• Positive Sentiment: Management raised or reaffirmed a favorable 2026 outlook, calling for EPS of $0.700-$0.720 versus analyst expectations of $0.680. Revenue guidance was approximately $1.5 billion, broadly in line with consensus, suggesting profitability is expected to outperform despite modest top-line expectations.
• Positive Sentiment: The company is targeting €335 million to €345.2 million in adjusted EBITDA for 2026 following the divestiture of Balda C. Brewer. The target gives investors a clearer view of expected profitability after the portfolio change. Stevanato targets adjusted EBITDA following Balda C. Brewer divestiture
• Neutral Sentiment: The earnings-call coverage focused on the company’s second-quarter performance, updated guidance and strategy following the divestiture. Investors are likely looking for further detail on demand trends, margins and the pace of growth during the call. Stevanato Group Q2 2026 Earnings Call Transcript
• Negative Sentiment: Reported quarterly EPS was mixed: one report cited €0.14 versus a €0.15 consensus estimate, while another cited $0.16 versus a $0.15 estimate. The conflicting figures may be creating uncertainty, but the reported miss in the company’s local-currency presentation could be weighing on the stock despite the stronger guidance.

About Stevanato Group

Stevanato Group is a global provider of primary packaging solutions and related services for the pharmaceutical and biotech industries. The company specializes in the design, development and manufacturing of glass drug containers such as vials, cartridges and pre-fillable syringes, as well as advanced inspection systems and assembly equipment. Its integrated offerings cover the entire packaging supply chain, from component production to bespoke filling lines and serialization technology.

In addition to its core glass business, Stevanato Group delivers engineering services and process validation support to pharmaceutical customers.